Stuart C. Gordon

Stuart C. Gordon's AcademicInfluence.com Rankings

Stuart C. Gordon

Physics

#8103

Historical Rank

physics Degrees

Download Badge

Physics

Stuart C. Gordon's Degrees

Bachelors Physics Stanford University

Why Is Stuart C. Gordon Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stuart C. Gordon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial (2001) (6290)
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. (1998) (3524)
Sofosbuvir for previously untreated chronic hepatitis C infection. (2013) (1815)
Boceprevir for previously treated chronic HCV genotype 1 infection. (2011) (1711)
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. (1998) (1334)
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. (2014) (1329)
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. (2014) (1153)
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. (2013) (1122)
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. (2009) (905)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015) (764)
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (2010) (733)
A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C (2001) (651)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. (2015) (466)
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. (2018) (457)
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection (2017) (452)
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. (2007) (450)
Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. (2004) (442)
Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. (2005) (380)
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study (2014) (342)
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. (2004) (337)
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial (2013) (315)
A Randomized , Double-Blind Trial Comparing Pegylated Interferon Alfa-2 b to Interferon Alfa-2 b as Initial Treatment for Chronic Hepatitis C (2001) (273)
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. (2017) (267)
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection (2010) (251)
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. (2016) (211)
Factors that predict response of patients with hepatitis C virus infection to boceprevir. (2012) (209)
The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. (2000) (201)
Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. (2012) (175)
Serum Ferritin Level Predicts Advanced Hepatic Fibrosis among U.S. Patients with Phenotypic Hemochromatosis (2003) (175)
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment (2017) (174)
Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. (2015) (171)
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. (2015) (169)
Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. (2013) (159)
Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. (2019) (158)
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. (2015) (147)
The pathology of hepatitis C as a function of mode of transmission: Blood transfusion vs. Intravenous drug use (1993) (135)
Prolonged intrahepatic cholestasis secondary to acute hepatitis A. (1984) (133)
Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. (2015) (133)
Clinical outcome of hepatitis C as a function of mode of transmission (1998) (132)
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. (2016) (129)
Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. (2013) (129)
Phase 1B, randomized, double‐blind, dose‐escalation trial of CPG 10101 in patients with chronic hepatitis C virus (2007) (127)
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. (2018) (127)
Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. (2014) (123)
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. (2014) (118)
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure (2018) (116)
Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection (2012) (110)
Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C (1998) (110)
Cryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis. (1994) (107)
Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. (1986) (106)
Antibodies to carbonic anhydrase in patients with immune cholangiopathies. (1995) (106)
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load (2013) (106)
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. (2017) (104)
Cost-effectiveness of screening for chronic hepatitis C infection in the United States. (2011) (103)
Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens. (2005) (102)
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. (2015) (98)
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. (2012) (97)
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. (2016) (97)
4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C (2009) (84)
The Burden of Acute Nonfulminant Drug-induced Hepatitis in a United States Tertiary Referral Center (2005) (82)
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy (2011) (81)
Lack of evidence for the heterosexual transmission of hepatitis C. (1992) (80)
Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. (2000) (79)
The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C (2000) (78)
12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY (2011) (78)
Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin (2013) (77)
The spectrum of liver disease in the acquired immunodeficiency syndrome. (1986) (77)
Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: The Chronic Hepatitis Cohort Study (CHeCS) (2015) (76)
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. (2013) (75)
2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID (2010) (73)
Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment (2001) (73)
Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. (2005) (73)
Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis (2011) (73)
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data (2020) (68)
Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment (2017) (66)
Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. (1999) (63)
The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. (2005) (61)
All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. (2016) (60)
All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus. (2016) (60)
Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis (2014) (60)
Advancing Age and Comorbidity in a US Insured Population‐Based Cohort of Patients With Chronic Hepatitis B (2019) (57)
Extrahepatic manifestations of hepatitis C. (1996) (57)
Levels of hepatitis C virus RNA and liver histology in chronic type C hepatitis. (1994) (57)
Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. (2018) (57)
4 PROVE1: RESULTS FROM A PHASE 2 STUDY OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH HEPATITIS C (2008) (57)
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. (2016) (54)
Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection (2010) (53)
104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS (2008) (53)
995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC (2008) (51)
Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification (1998) (50)
751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results (2006) (50)
Celecoxib-induced cholestatic hepatitis. (2001) (50)
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. (2018) (49)
Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy‐proven histological damage (2010) (49)
Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices (2020) (48)
1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 (2011) (48)
Phase 1 b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection (2010) (46)
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. (2014) (45)
Prolonged Intrahepatic Cholestasis and Renal Failure Secondary to Anabolic Androgenic Steroid-Enriched Dietary Supplements (2009) (45)
Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection. (2016) (44)
Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention (2015) (43)
Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems (2017) (41)
11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS (2012) (41)
Differences in Hepatic Phenotype Between Hemochromatosis Patients With HFE C282Y Homozygosity and Other HFE Genotypes (2009) (41)
Assessment of hepatitis B virus DNA and hepatitis C virus RNA in the common bedbug (Cimex lectularius L.) and kissing bug (Rodnius prolixus). (2001) (40)
Relationships between Hepatic Iron Content and Virologic Response in Chronic Hepatitis C Patients Treated with Interferon and Ribavirin (2005) (39)
Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study (2015) (39)
Pegylated interferon alfa-2B (PEG-intron) mono-therapy is superior to interferon alfa-2B (intron A) for the treatment of chronic hepatitis C (2000) (38)
Infrequent Clinical Assessment of Chronic Hepatitis B Patients in United States General Healthcare Settings. (2016) (38)
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States (2016) (37)
Mumps arthritis: a review of the literature. (1984) (37)
Mumps arthritis: unusual presentation as adult Still's disease. (1982) (37)
Assessment of hepatitis B virus DNA and hepatitis C virus RNA in the common bedbug (Cimex lectularius L.) and kissing bug (Rodnius prolixus) (2001) (36)
Uptake of and Factors Associated With Direct-acting Antiviral Therapy Among Patients in the Chronic Hepatitis Cohort Study, 2014 to 2015 (2017) (35)
Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma (2016) (34)
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. (2013) (33)
Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes (2019) (33)
Alfa interferon treatment of hepatitis C virus RNA-positive patients with normal or near-normal alanine aminotransferase levels. (1997) (32)
Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. (2013) (31)
High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study (2016) (30)
Portal tract eosinophils and hepatocyte cytokeratin 7 immunoreactivity helps distinguish early-stage, mildly active primary biliary cirrhosis and autoimmune hepatitis. (2001) (29)
CASE REPORT: Trovafloxacin Hepatotoxicity (2001) (29)
Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. (2019) (28)
[786] RESULTS OF AN INTERIM ANALYSIS OF A PHASE 2 STUDY OF TELAPREVIR (VX-950) WITH PEGINTERFERON a-2a AND RIBAVIRIN IN PREVIOUSLY UNTREATED SUBJECTS WITH HEPATITIS C (2007) (28)
Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. (1999) (28)
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. (2005) (28)
2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1) (2010) (27)
Treating Medicaid patients with hepatitis C: clinical and economic impact. (2017) (27)
Impact of sustained virologic response on risk of type 2 diabetes among hepatitis C patients in the United States (2018) (27)
Treatment of HBV/HCV coinfection: releasing the enemy within. (2009) (27)
Resistance-Associated Amino Acid Variants Associated with Boceprevir plus Pegylated Interferon-α2B and Ribavirin in Patients with Chronic Hepatitis C in the Sprint-1 Trial (2013) (26)
10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB (2012) (26)
Tattoo application is not associated with an increased risk for chronic viral hepatitis (2000) (26)
1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY? (2012) (26)
Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. (2002) (25)
Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C (2018) (25)
Trends in HCV RNA testing among HCV antibody-positive persons in care, 2003-2010. (2014) (24)
Patient‐Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir (2017) (24)
Bioelectrical Impedance Analysis for the Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis C Infection (2008) (24)
A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma (2009) (23)
Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy (2003) (23)
MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure (2017) (23)
Adefovir dipivoxil in chronic hepatitis B: history and current uses (2012) (23)
Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS) (2018) (23)
Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS) (2018) (23)
Epidemiology of Hepatitis C (2018) (22)
The value of cure associated with treating treatment‐naïve chronic hepatitis C genotype 1: Are the new all‐oral regimens good value to society? (2017) (22)
Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. (2019) (22)
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders (2009) (22)
HCV RNA is present in the menstrual blood of women with chronic hepatitis C infection. (1993) (21)
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. (2018) (21)
O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS (2014) (21)
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. (2020) (21)
Hepatitis B virus infection testing and prevalence among Asian and Pacific Islanders. (2014) (20)
Chronic Hepatitis C Infection as a Risk Factor for Renal Cell Carcinoma (2015) (20)
Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials (2015) (20)
Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS) (2016) (20)
Validity of an automated algorithm using diagnosis and procedure codes to identify decompensated cirrhosis using electronic health records (2017) (20)
Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. (2018) (20)
Trovafloxacin hepatotoxicity (2000) (20)
Comparison of ICD-9 Codes for Depression and Alcohol Misuse to Survey Instruments Suggests These Codes Should Be Used with Caution (2017) (19)
High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1–6 patients without cirrhosis (2017) (19)
Focal hepatic candidiasis with perihepatic adhesions: laparoscopic and immunohistologic diagnosis. (1990) (18)
New insights into acute hepatitis C. (2003) (18)
744 Sustained virologic response (SVR) to interferon-alpha-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up (2006) (18)
Role of Liver Biopsy in the Era of Direct-Acting Antivirals (2013) (18)
Use of the methacetin breath test to classify the risk of cirrhotic complications and mortality in patients evaluated/listed for liver transplantation. (2015) (18)
45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients (2004) (18)
Boceprevir Resistance-Associated Variants (Ravs) Are Observed More Frequently in HCV (GT1)-Infected Patients With Poor Response to Peginterferon Alfa-2B/Ribavirin (2011) (17)
MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure (2017) (17)
Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006–2013 (2016) (17)
Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment. (2017) (17)
Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA (2022) (17)
Locations and Reasons for Initial Testing for Hepatitis C Infection — Chronic Hepatitis Cohort Study, United States, 2006–2010 (2013) (17)
Experimental evidence against replication or dissemination of hepatitis C virus in mosquitoes (Diptera:Culicidae) using detection by reverse transcriptase polymerase chain reaction. (1996) (16)
Is Previous Exposure to Hepatitis B a Risk Factor for Pancreatic Cancer or Hepatocellular Carcinoma? (2014) (16)
Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States (2017) (16)
9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (16)
M1908 Tenofovir Disoproxil Fumarate (TDF) for the Treatment of HBeAg-Negative Chronic Hepatitis B: Week 72 TDF Data and Week 24 Adefovir Dipivoxil Switch Data (Study 102) (2008) (15)
Adjuvant ribavirin and longer direct‐acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure (2019) (15)
Sustained virological response does not improve long‐term glycaemic control in patients with type 2 diabetes and chronic hepatitis C (2019) (15)
Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE) (2017) (14)
312 Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks (2003) (14)
Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium (2017) (14)
865 12 WEEK RESPONSE-GUIDED TREATMENT WITH THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, PLUS PEGYLATED INTERFERON/RIBAVIRIN IN TREATMENT NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS (2013) (14)
Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavir in in Patients With Chronic Hepatitis C (CHC), Genotype 1 (G1) (2010) (14)
Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C (2016) (14)
Adherence to Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C Genotype 1 Treatment-NaïVE and PEG/Ribavirin Treatment-Failures Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin (2011) (13)
Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus — CDC Guidance, United States, 2020 (2020) (13)
Successful treatment of hepatitis B-associated vasculitis with lamivudine. (2001) (13)
Mitochondrial antigens as targets of cellular and humoral auto-immunity in primary biliary cirrhosis (2005) (13)
Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases (2020) (13)
Changing trends in complications of chronic hepatitis C (2018) (13)
Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems. (2017) (12)
Major hemorrhage after percutaneous liver biopsy in patients with AIDS. (1991) (12)
Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence (2020) (12)
Epidemiology of hepatitis C virus infection in a suburban Detroit community. (1991) (12)
Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. (2020) (12)
Budd-Chiari syndrome complicating pre-eclampsia: diagnosis by magnetic resonance imaging. (1991) (12)
Mental and physical health status among chronic hepatitis B patients (2020) (11)
Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry. (2021) (11)
428 ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (11)
6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL (2013) (11)
5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION) (2013) (11)
LBP-13-Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort (2019) (11)
Risk Factors for Hepatitis C Infection Among Vietnam Era Veterans Versus Nonveterans: Results from the Chronic Hepatitis Cohort Study (CHeCS) (2014) (11)
Current pharmacotherapy for hepatitis B infection (2001) (11)
A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients (2013) (10)
Hepatitis A and B immunity and vaccination in chronic hepatitis B and C patients in a large United States cohort. (2015) (10)
Gastrointestinal hemorrhage secondary to crack cocaine. (1995) (10)
Comparative histologic features of liver biopsy specimens from patients coinfected with hepatitis G and C viruses with chronic hepatitis C virus alone: an age-, sex-, disease duration-, and transmission-matched controlled study of chronic hepatitis. (1997) (10)
Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. (2017) (10)
804 SUSTAINED VIROLOGIC RESPONSE AFTER PEGINTERFERON ALFA-2B AND RIBAVIRIN TREATMENT PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR FOLLOW-UP (2008) (10)
Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure (2020) (10)
No Impact of Rass on the High Efficacy of SOF/VEL/VOX for 12 Weeks in Daa-Experienced Patients: An Integrated Resistance Analysis of the Polaris-1 and Polaris-4 Studies (2017) (9)
[649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA (2007) (9)
Novel Therapies in Hepatic Encephalopathy. (2020) (9)
Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017 (2020) (9)
Long‐term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B (2017) (9)
Occult Viral Hepatitis and Noncirrhotic Hepatocellular Carcinoma (2005) (9)
Histologic spectrum of cryptogenic chronic liver disease and comparison with chronic autoimmune and chronic type C hepatitis. (1995) (9)
Baricitinib and primary biliary cholangitis (2021) (9)
S1001 Clearance of HCV At 5 Year Follow-Up for Peginterferon Alfa-2b ± Ribavirin Is Predicted By Sustained Virologic Response At 24 Weeks Post Treatment (2008) (8)
Autoantibodies to specific enzymes: a review. (1996) (8)
Comparative Effectiveness Research of Chronic Hepatitis B and C Cohort Study (CHeCS): Improving Data Collection and Cohort Identification (2014) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
223 Prove1: Results from a Phase 2 Study of Telaprevir with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Hepatitis C (2008) (8)
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. (2022) (8)
High SVR Rates with Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis (2017) (8)
All-oral Dual Therapy with Daclatasvir and Asunaprevir in Patients with HCV Genotype 1B Infection (2014) (7)
Acute Hepatitis B in an Urban Tertiary Care Hospital in the United States: A Cohort Evaluation (2013) (7)
Prevalence of anti-HCV in cryptogenic cirrhosis in a suburban Detroit community. (1992) (7)
A flow cytometric method to detect anti-pyruvate dehydrogenase antibody in primary biliary cirrhosis. (1992) (7)
964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC) (2012) (7)
HLA haplotypes in primary sclerosing cholangitis patients of admixed and non‐European ancestry (2017) (7)
Anabolic steroid-induced cholestasis: choleretic response to corticosteroids. (1988) (7)
Treatment of viral hepatitis - 2001 (2001) (7)
111 Final results of a multi-center phase 1b, randomized, placebo-controlled, doseescalation trial of CPG 10101 in patients with chronic hepatitis C virus (2006) (7)
IMO-2125, A TLR9 AGONIST, INDUCES IMMUNE RESPONSES WHICH CORRELATE WITH REDUCTIONS IN VIRAL LOAD IN NULL RESPONDER HCV PATIENTS (2010) (7)
O001 : C-salvage: grazoprevir (GZR; MK-5172), elbasvir (EBR; MK-8742) and ribavirin (RBV) for chronic hcv-genotype 1 (GT1) infection after failure of direct-acting antiviral (DAA) therapy (2015) (7)
Renal insufficiency after liver transplantation in the MELD era compared to the pre‐MELD era (2009) (6)
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data (2022) (6)
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study (2020) (6)
BUDD-CHIARI AND INFARCT IN PREGNANCY (1999) (6)
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts (2021) (6)
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml) (2015) (6)
Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis (2019) (6)
Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy (2012) (6)
Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score (2020) (6)
628 RANDOMIZED TRIAL COMPARING SYSTEMIC AND LOCAL REACTIONS TO CONTROLLED-RELEASE INTERFERON ALPHA2B AND PEGYLATED-INTERFERON ALPHA2B IN HEPATITIS C PATIENTS WHO FAILED PRIOR TREATMENT (2009) (6)
Hepatitis C screening: summary of recommendations from the clinical decision tool. (2013) (5)
764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study (2014) (5)
Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States (2020) (5)
818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR (2013) (5)
Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States (2022) (5)
836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim Results (2012) (5)
Hepatitis C Virus Detection and Treatment in Rural Communities. (2018) (5)
Scintigraphic and culdoscopic diagnosis of bile peritonitis complicating liver biopsy. (1989) (5)
Hepatitis B Virus Infection and Hepatitis C Virus Treatment in a Large Cohort of Hepatitis C-Infected Patients in the United States. (2018) (5)
THU-405-Complications of chronic hepatitis B: Prevalence and disparities in a US health system cohort 2006-2016 (2019) (5)
Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 (2019) (5)
Predictors of consent to pharmacogenomics testing in the IDEAL study (2011) (5)
Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B (2013) (5)
Normal alkaline phosphatase levels are dependent on race/ethnicity: National Health and Nutrition Examination Survey data (2020) (5)
Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study (2016) (5)
Case report: Acute type a hepatitis presenting with hypotension, bradycardia, and sinus arrest (1989) (5)
P1171 INTEGRATED SAFETY ANALYSIS OF SOFOSBUVIR-BASED HCV TREATMENT REGIMENS FROM PHASE 3 STUDIES (2014) (4)
745 Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV associated thrombocytopenia: Preliminary results from a phase II dose-ranging study (2006) (4)
Impact of sustained virological response on incidence of type 2 diabetes in hepatitis c patients. (2017) (4)
Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) (4)
Availability of PEth testing is associated with reduced eligibility for liver transplant among patients with alcohol‐related liver disease (2022) (4)
P374 LONG-TERM TREATMENT OF PRIMARY BILIARY CIRRHOSIS WITH THE FXR AGONIST OBETICHOLIC ACID SHOWS DURABLE EFFICACY (2014) (4)
Advancing Age and Comorbidities in Chronic Hepatitis B Patients: Results of 10-Year Longitudinal Analysis of a Diverse Population-Based Cohort of 44,026 Chronic Hepatitis B Patients in the United States (2017) (4)
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection (2019) (4)
Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study (2015) (4)
Higher and Rising Prevalence and Incidence of Renal Impairment and Chronic Kidney Disease in Chronic Hepatitis B Patients Compared to Matched Non-Chronic Hepatitis B Controls in the United States: Results of a Real-World Analysis (2017) (4)
Hepatic Manifestations of Systemic Disorders (2011) (4)
HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape (2015) (4)
P0889 : Effect of baseline factors on response to the fixed-dose combination of daclatasvir (DCV), asunaprevir (ASV) and beclabuvir (BCV) in non-cirrhotic patients with HCV genotype 1 infection (2015) (4)
952 LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC) (2012) (4)
Efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis: 52-week analysis of an ongoing international, randomized, dose ranging phase 2 study. (2018) (4)
1181 PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL IL-28B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN (2010) (3)
IDDF2018-ABS-0113 The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis (2017) (3)
INCREASING INCIDENCE OF HEPATOCELLULAR CARCINOMA IN THE UNITED STATES: TRENDS IN A CLINICAL HEPATOLOGY PRACTICE (2004) (3)
Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis (2016) (3)
Hepatitis C Virus-Associated Aortitis Caused by Type I Cryoglobulins (2017) (3)
Jaundice and cholestasis. Some common and uncommon causes. (1991) (3)
Antiviral therapy for chronic hepatitis B and C (2000) (3)
The safety of daclatasvir for the treatment of hepatitis C (2015) (3)
A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Trial of Merimepodib (VX-497) and Interferon-α in Previously Untreated Patients with Chronic Hepatitis C (2005) (3)
Immunoglobulin M antibody to hepatitis B core antigen and fulminant hepatitis B. (1985) (3)
Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis (2017) (3)
Increasing healthcare resource utilization (HCRU) and costs associated with advanced liver disease-a multivariate analyses of real-world medicare nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/ NASH) patients. (2018) (3)
647 TREATMENT OF HEPATITIS C WITH THE IMMUNE- STIMULATING DIPEPTIDE SCV-07 (2009) (3)
Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life? (2020) (3)
Does Hepatitis C eradication lead to improved glucose metabolism, renal and cardiovascular outcomes in diabetic patients? (2017) (3)
Prevalence of Osteoporosis and Bone Fracture was 2-Fold Higher in Chronic Hepatitis B Compared to Non-Chronic Hepatitis B Patients and Continued to Increase in the Last Decade: Results of a United States Population-Based Cohort Study (2017) (3)
Trends in Diagnosed Chronic Hepatitis B in a US Health System Population, 2006–2015 (2019) (3)
Utility of IL-28B Polymorphisms in the Era of Direct-Acting Antiviral Therapy. (2011) (2)
Management of Chronic Viral Hepatitis (2001) (2)
Immunological responses in patients who have spontaneously eradicated hepatitis C virus infection. (2000) (2)
[632] IMPACT OF TARIBAVIRIN EXPOSURE ON EFFICACY, ANEMIA RATES, AND Gl SIDE EFFECTS WHEN USED WITH PEGYLATED INTERFERON ALFA-2b FOR THE TREATMENT OF CHRONIC HEPATITIS C (2007) (2)
Boceprevir Plus Peginterferon &agr;-2b/Ribavirin in Chronic Hepatitis C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response (2013) (2)
IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies (2017) (2)
Polycystic Liver Disease. (2015) (2)
Management of Direct‐Acting Antiviral Failures (2020) (2)
Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6: 412 (2013) (2)
Cost-effectiveness analysis of first-line administration of tenofovir alafenamide (TAF), a novel nucleotide reverse transcrip-tase inhibitor (NRTI), for the management of chronic hepatitis b (CHB) in the united states (us). (2017) (2)
3 Times Higher Healthcare Cost in Chronic Hepatitis B Patients Compared to Non-Chronic Hepatitis B Controls Especially Those with Decompensated Liver Disease: United States Real World Healthcare Utilization and Cost Analysis (2017) (2)
650 Integrated Safety Analysis of Sofosbuvir-Based HCV Treatment Regimens From Phase 3 Studies (2014) (2)
A Case of Hemophagocytic Lymphohistiocytosis Secondary to Disseminated Histoplasmosis (2020) (2)
A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C (2017) (2)
Serum bilirubin within normal range is associated with an increasing risk of mortality in patients with primary biliary cholangitis regardless of ursodeoxycholic acid treatment. Hepatology 2018; 68:31A-32A. (2018) (2)
Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C. (2020) (2)
Preliminary results of the NYNEST interferon-Ribavirin re-treatment trial in non-responders and relapsers with chronic hepatitis C (1998) (2)
Laparoscopic diagnosis of subcapsular hepatic hemorrhage in pre-eclamptic liver disease. (1992) (2)
C-BREEZE 1: Efficacy and safety of ruzasvir 60 mg plus uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis c virus (HCV) genotype (GT)1, 2, 3, 4, or 6 infection. (2017) (2)
1116 EXPOSURE-RESPONSE RELATIONSHIPS IN TELAPREVIR COMBINATION THERAPY IN TREATMENT-NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS (2012) (2)
Sa1046 Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA=9 Log10 Copies/Ml) (2012) (2)
Care of the cirrhotic patient. (2012) (2)
Epidemiologic trends and treatment survival benefits in a US cohort of patients with primary biliary cholangitis (PBC). (2017) (2)
Corrigendum: Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis (2014) (2)
896 - Utilization and Expenditures for Non-Alcoholic Steatohepatitis/Non-Alcoholic Fatty Liver Disease Patients with Advance Fibrosis and Compensated Cirrhosis: Results of a Real-World Analysis Among us Patients (2018) (2)
1202 Comparison of low dose with standard dose PEG-interferon alfa-2B plus rivavirin for initial treatment of chronic hepatitis C (2003) (2)
Rising and higher healthcare resource utilization (HCRU) and costs of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) patients with advanced liver disease of increasing severity-results of a US real-world analysis. (2018) (2)
748 United States Multicenter Study of Ultrasonic TRANSIENT ELASTOGRAPHY (FibroScan) for the Diagnosis of Cirrhosis and Fibrosis in Patients with Hepatitis B and C (2009) (2)
835 Exposure-Response Relationships in Telaprevir Combination Therapy in Treatment-NaïVE Genotype 1 Chronic HCV Patients (2012) (2)
Viral hepatitis: Practical evaluation and treatment. By Teddy F. Bader. 248 pp. Seattle: Hogrefe & Huber, 1994. $49 (1995) (1)
The Impact of Patient Preferences on Pancreatic Cyst Management: 229 (2013) (1)
African Americans Demonstrate Significantly Lower Serum Alanine Aminotransferase Compared to Non-African Americans (2020) (1)
Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
Tu1497 – Efficacy and Safety of Sofosbuvir/Velpatasvir for the Treatment of Patients with Chronic Hepatitis C Genotype 1-6 Infection: Integrated Analysis of Eight Phase 3 Clinical Trials (2019) (1)
"Love Boat" hepatitis. (1985) (1)
Choledochocele: its clinical spectrum. (1985) (1)
Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities. (2019) (1)
M1907 Efficacy of Entecavir in Nucleoside-NaïVe Patients with Mildly Elevated ALT (2008) (1)
1001 Relationship between hepatic iron content and histological response in chronic hepatitis C (2003) (1)
329 THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR) (2020) (1)
Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA (2021) (1)
408 WATS Brushings Are More Sensitive for Detecting Intestinal Metaplasia in Barrett’s Esophagus Than Concurrent Forceps Biopsies: Results From a National Registry (2019) (1)
468 UNIQUE PATTERN OF VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE-1 HCV: A PHASE II STUDY OF CTS-1027 IN COMBINATION WITH PEGINTERFERON/RIBAVIRIN (SOC) IN NULL RESPONDERS (2011) (1)
The Consequences of Cirrhosis in America (2015) (1)
291 - Long-Term Follow-Up of Patients with Chronic HCV and F2 or F3 Fibrosis after Achieving SVR with Daa-Based Therapy: Results from the Gilead SVR Registry (2018) (1)
Higher Resource Utilization and Healthcare Costs in Treated Chronic Hepatitis B Patients with Chronic Kidney Disease (2017) (1)
Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study (2017) (1)
410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS (2011) (1)
Successful treatment of multi-drug resistant hepatis C after >12 months of continuous therapy with direct-acting antivirals. (2022) (1)
Occlusion Rate and Complications of Plastic Biliary Stents in Patients Undergoing Neoadjuvant Chemoradiotherapy for Pancreatic Cancer Associated with Biliary Obstruction: 237 (2008) (1)
Real world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in blacks with HCV: A comparative analysis of clinical trials with real world cohorts. (2017) (1)
Patient-reported outcomes in chronic hepatitis C: The impact of placebo, active treatment, and sustained viral eradication (2018) (1)
PS-122-Seladelpar for the treatment of primary biliary cholangitis: Experience with 26 cirrhotic patients (2019) (1)
High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4 (2017) (1)
Health outcomes associated with sofosbuvir- based single-tablet regimens for initial and re-treatment of chronic hepatitis c in the US. (2017) (1)
The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world (2020) (1)
Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: results from the Gilead SVR registry (2018) (1)
Update on Polycystic Liver Disease. (2020) (1)
The persistence of underreporting of hepatitis C as an underlying or contributing cause of death, 2011-2017. (2021) (1)
1254-P: Increased Health-Care Resource Utilization (HRU) and Costs among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients with Advanced Fibrosis (AF) having Diabetes Mellitus (DM) (2019) (1)
The burden of acute non-fulminant drug-induced liver disease in the United States (2003) (1)
294 - Retreatment of Patients who Failed Glecaprevir/Pibrentasvir Treatment for Hepatitis C Virus Infection (2018) (1)
Use of Billing and Procedure Codes to Predict Stage of Liver Disease in Patients with Chronic Viral Hepatitis: 496 (2013) (1)
P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS (2014) (1)
Post-transplant course of hepatitis C after living donor liver transplantation in association with polymorphisms near IFNL3. (2015) (1)
P0770 : Effect of hepatitis C antiviral therapy on all-cause mortality and development of cancer in the chronic hepatitis cohort study (CHeCS) (2015) (1)
P1034 ESTIMATED PREVALENCE OF HCV CIRRHOSIS IN THE CHRONIC HEPATITIS COHORT STUDY (CHECS) (2014) (1)
Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR) (2017) (1)
Fibrosis-4 score (FIB-4) provides consistent assessment of healthcare costs and healthcare resource utilization (HCRU) among nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients with advanced fibrosis. (2018) (1)
Resection of metachronous hepatocellular carcinomas. (1986) (1)
The Impact of Prior Biliary Stenting on the Accuracy and Complication Rate of EUS-FNA for Diagnosing Pancreatic Adenocarcinoma: 158 (2009) (1)
418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) (2011) (1)
Trends in Cirrhosis and Mortality by Age, Sex, Race, and Antiviral Treatment Status Among US Chronic Hepatitis B Patients (2006-2016) (2021) (1)
Rising Healthcare Utilization and Cost of Chronic Hepatitis B: Real-World Analysis of 44,026 Chronic Hepatitis B Patients and 121,568 Matched Non-Chronic Hepatitis B Controls in the United States (2017) (1)
IDDF2019-ABS-0134 Sofosbuvir/velpatasvir is effective and safe in patients with concomitant proton pump inhibitor use in clinical studies (2019) (1)
Love Boat" hepatitis. (1985) (1)
Virologic Response Rates to Fixed-Dose Combination Ledipasvir/Sofosbuvir for 8 or 12 Weeks With Baseline Viral Load: 2061 (2015) (0)
Liver diseases in the elderly. (1991) (0)
IDDF2018-ABS-0111 Safety and efficacy of treatment with once-daily LEDIPASVIR/SOFOSBUVIR (90/400 MG) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment (2018) (0)
Severe impairment of patient‐reported outcomes in patients with chronic hepatitis C virus infection seen in real‐world practices across the world: Data from the global liver registry (2022) (0)
High SVR Rates with 8 and 12 Weeks of Pangenotypic GlecapreviriPibrentasvir: PH2Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis (2017) (0)
SIRS is the Optimal Simple Predictor of Severity in Acute Pancreatitis: Presidential Poster: 226 (2013) (0)
Does the Type of Pancreatic Malignancy Influence the Number of Fine Needle Aspiration Attempts? A Comparison Between Pancreatic Adenocarcinoma and Islet Cell Neoplasms: 230 (2012) (0)
A Rare Cause for Persistent Esophageal Leak after Esophagectomy: Gastric Perforation from a Chest Tube: 589 (2012) (0)
S1208 Prevalence of Hepatitis B Virus (HBV) and Latent Tuberculosis Co-Infection and Risk of Drug-Induced Liver Injury Across Two Large HBV Cohorts in the United States (2022) (0)
62 CONSISTENT DNA METHYLATION DIFFERENCES IN 46 GENOME-WIDE LOCI IN MONOZYGOTIC TWINS DISCORDANT FOR PRIMARY BILIARY CIRRHOSIS (2010) (0)
812 A Cost-Effectiveness Analysis of LDV/SOF+RBV for 12 Weeks vs. LDV/SOF 24 Weeks vs. SOF+SMV 24 Weeks in CHC Gt1 TE Cirrhotic Patients (2015) (0)
Long-Term Fibrosis and Viral Level Progression among Treated and Untreated Patients with Chronic Hepatitis B (2016) (0)
Reevaluation of the Upper Limit of Normal for Outpatient Alanine Aminotransferase (ALT) Levels at a Large United States Urban Medical Center: 436 (2014) (0)
Presence of advanced liver disease concurrent with initial diagnosis of Hepatitis C virus (HCV) infection among patients in the chronic hepatitis cohort study (CHECS) 2014-16: Missed opportunities for intervention. (2018) (0)
Second Generation Protease Inhibitors and Nucleotide Inhibitors (2012) (0)
Sacrificing Affordability in the Name of Proving Efficacy: The Case of Pancreatic Enzyme Replacement Therapy: 224 (2013) (0)
Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™ (2023) (0)
Tu2049 Projection of Health Outcomes Comparing LDV/SOF vs. SOF+SMV - An Analysis Based on Clinical Trial vs. Real-World Data (2015) (0)
Health and economic outcomes of sofosbuvir therapy as predicted by a Markov model in the HCV/HIV co-infected cohort (2014) (0)
Non-Invasive Predictors of Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: 266 (2005) (0)
Extended Re-Treatment for Chronic Hepatitis C Genotype 1 Patients Who Previously Relapsed Following 48 Week PEG/Ribavirin Therapy: 430 (2006) (0)
Recurrent Appendicitis; Six Operations with Six Recoveries; Treatment for Acute Attack in Five Cases (1893) (0)
Sa313 CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY™ (2021) (0)
HIV co-infection is associated with increased liver complications and reduced mental health among patients with chronic hepatitis B (2018) (0)
Lean non-alcoholic fatty liver disease patients from the global NASH registry (2022) (0)
Diagnosis and management of chronic hepatitis C virus infection (2001) (0)
765 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RESPONSE (RPCDBDR) TRIAL OF CTS-1027, AN INHIBITOR OF MATRIX METALLOPROTEASES (MMPS) IN PATIENTS WITH HCV WHO HAD FAILED PRIOR THERAPIES (2010) (0)
Staufferʼs Syndrome: Renal Cell Carcinoma Presenting as Abnormal LFTs: 735 (2015) (0)
PE-056 : The Safety and Tolerability of SOF/VEL/VOX for 8/12 Weeks in >1,000 Patients Treated in the POLARIS Studies: An Integrated Analysis (2017) (0)
Response to: ‘No impact of Covid‐19 pandemic on decompensation of alcoholic liver disease: Results from a single Center in Milan’ (2022) (0)
CB3-02: Demographic Differences Between US-born and Foreign-born Asia Pacific Islanders Among the Hepatitis B Patients of Kaiser Permanente, Hawai’i (2012) (0)
O.105 Early clinical results with CPG 10101, a new investigational antiviral TRL9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus (2006) (0)
Reporting of Findings on EUS Examinations for Chronic Pancreatitis: Toward Establishing Benchmarks for EUS Quality: 231 (2012) (0)
Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIES (2022) (0)
Endoscopic Ultrasound-Guided Gastro-gastrostomy for Surveillance of Gastric MALT Lymphoma in a Roux-en-Y Gastric Bypass Patient: 2047 (2017) (0)
P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS (2014) (0)
Air Embolism: A Rare Complication of ERCP: 803 (2012) (0)
Minocycline hepatitis: clinical and histopathologic features and comparison with autoimmune hepatitis (2000) (0)
Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct-acting antivirals. (2023) (0)
P0778 : The effect of HCV antiviral therapy on fibrosis progression (2015) (0)
PARAESOPHAGEAL VARICES MIMICKING A MEDIASTINAL MASS MADE APPARENT BY ENDOSCOPIC ULTRASOUND: 574 (2004) (0)
Body Mass Index Does Not Impact the Efficacy of Avatrombopag in Increasing Platelet Counts and Reducing Platelet Transfusions or Rescue Procedures for Bleeding in Cirrhotic Patients with Thrombocytopenia: Presidential Poster Award (2018) (0)
MST Criteria to Diagnose Chronic Pancreatitis Are Inaccurate Among Expert Endosonographers: 235 (2014) (0)
HEPATITIS C AS A RISK FACTOR FOR RENAL CELL CARCINOMA (2009) (0)
Anabolic Steroid Induced Cholestasis Secondary to a Dietary Supplement: 942 (2006) (0)
Comparative analysis of direct-acting antiviral regimens across Hepatitis C genotypes and clinical characteristics among patients under routine clinical care in the US. (2018) (0)
S1010 Effect of Renal Function On Dose Reduction and Sustained Viral Response in Patients with Hepatitis C Treated with Pegylated Interferon and Ribavirin (2008) (0)
Mo1919 Chronic Aminotransferase Elevation Confounds Transient Elastography in HCV Patients With Early Stage Fibrosis (2012) (0)
Mo1168 Reduction in Clinical and Economic Burden by Treating All Medicaid Patients With Chronic Hepatitis C (CHC): A Decision-Analytic Model (2016) (0)
HEREDITARY HEMORRHAGIC TELANGIECTASIA AND SYMPTOMATIC LIVER DISEASE: 561 (2004) (0)
FRI-023-Inadequate response to UDCA among PBC patients under routine care in the US: Rising serum bilirubin even in the normal range is a risk factor and subsequent clinical follow-up differs based on treatment response (2019) (0)
P0729 : Renal disease prevalence and association with hepatic fibrosis measured by FIB4 score among US patients with chronic hepatitis C virus (HCV) infection in the chronic hepatitis cohort study (CHeCS) (2015) (0)
P1052 DETERMINANTS OF VARIABILITY IN ISG15 GENE EXPRESSION IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) INFECTION DURING TREATMENT WITH ORAL TLR7 AGONIST GS-9620 (2014) (0)
Survival Effect of Palliative Cryoablation Therapy in Patients With Locally Advanced Esophageal Cancer: 2017 Presidential Poster Award: 318 (2017) (0)
Rare Case of Acute Liver Failure Caused by Diffuse Liver Metastases in a Patient With Non-Muscle Invasive Transitional Cell Carcinoma of the Bladder: 1323 (2014) (0)
Abnormal Duodenal [HCO3-] Following Secretin Stimulation Develops Sooner than Endocrine Insufficiency in Minimal Change Chronic Pancreatitis: 189 (2010) (0)
High Burden of GI Disease and Unmet Need in Rwanda: Findings From Rwanda Endoscopy Week (2018) (0)
P748 CHRONIC HEPATITIS C INFECTION AS A RISK FACTOR FOR RENAL CELL CARCINOMA (2014) (0)
PIN26 COST-MINIMIZATION ANALYSIS OF PAN-GENOTYPIC TREATMENT REGIMENS FOR CHRONIC HEPATITIS C (2019) (0)
P511 USE OF C-METHACETIN BREATH TEST (MBT) TO PREDICT CIRRHOSIS COMPLICATIONS AND MORTALITY IN PATIENTS WITH LOW MELD SCORES EVALUATED OR LISTED FOR LIVER TRANSPLANTATION (LT) (2014) (0)
686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDY (2020) (0)
Mode of transmission predicts, clinical outcome in chronic hepatitis C: An age matched study comparing injection drug users and transfusion recipients (1998) (0)
Don’t Forget the Cameron Lesion: A Rare Cause of Obscure Gastrointestinal Bleeding (OGB): 865 (2014) (0)
474 A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated Patients and Those Without Treatment Options With Chronic Hepatitis C Virus (2014) (0)
Substantial healthcare utilization (HCU) and costs among non-alcoholic steatohepatitis (NASH) patients with comorbid diabetes mellitus (DM): Real-world analysis of 2007–2015 US Medicare data (2018) (0)
Predicting Relapse to Pegylated Interferon and Ribavirin Therapy According to First HCV RNA Negativity: 341 (2005) (0)
Non-Hodgkin B-Cell Lymphoma in Hepatitis C Virus Infection (2018) (0)
A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated Patients and Those Without Treatment Options with Chronic Hepatitis C Virus Genotype 2 Infection (2013) (0)
Mo1473 – Seladelpar for the Treatment of Primary Biliary Cholangitis: Experience with 26 Cirrhotic Patients (2019) (0)
342 CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY (2021) (0)
RIBA-3 HCV-positive/PCR-negative patients have T cell immunity indicating prior infection (1998) (0)
IDDF2020-ABS-0060 Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF (2020) (0)
35 – Hepatitis A (2018) (0)
Effect of SVR on liver-related and all-cause hospitalization of patients with chronic HCV infection: The chronic hepatitis cohort study (CHECS), 2014-16. (2018) (0)
PATIENT CHARACTERISTICS AND EFFICACY OF PANGENOTYPIC DIRECT-ACTING ANTIVIRAL REGIMENS AMONG A COHORT OF CHRONIC HEPATITIS C PATIENTS RECEIVING ROUTINE CLINICAL CARE IN THE US (2020) (0)
Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary Cholangitis (2020) (0)
Hepatitis C patients with HIV co-infection demonstrate unique liver-related complications and health behaviors compared to HCV mono-infected patients (2018) (0)
The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology (2017) (0)
Lower rates of emergency visits and hospitalizations among chronic hepatitis C patients with sustained virological response to interferon-free direct-acting antiviral therapy (2014-2018). (2022) (0)
Evolving Screening and Vaccination Recommendations for Hepatitis B in the USA (2022) (0)
Direct Healthcare Costs Associated with Osteoporosis and Bone Fracture in Pharmacologically Treated Chronic Hepatitis B Patients: Results of A United States Population-Based Cohort Study (2017) (0)
Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies. (2021) (0)
Cryotherapy for Palliation of Malignant Dysphagia: 3 (2013) (0)
Sa1492 - HIV Co-Infection is Associated with Increased Liver Complications and Reduced Mental Health Among Patients with Chronic Hepatitis B (2018) (0)
HEPATITIS C VIRUS AS A CO-FACTOR IN AZATHIOPRINE-INDUCED CHOLESTASIS: 594 (2004) (0)
IDDF2020-ABS-0057 Risk of incident hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) virus-infected patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV): a US administrative claims analysis (2020) (0)
Treatment of unresectable hepatocellular carcinoma using intra-arterial yttrium-90 (TheraSphere): Report of a pilot trial (2003) (0)
Is there still a role for liver biopsy in managing hepatitis C virus infections? (2012) (0)
S2392 Diagnosis and Management of Spontaneous Splenorenal Shunts (2020) (0)
Laboratory monitoring and antiviral treatment for chronic hepatitis B among routine care patients in the United States (2021) (0)
PS2-10: Predictors of Depression and Poor Physical Health among Patients with Chronic Hepatitis C Infection: Results from the Chronic Hepatitis Cohort Study (2014) (0)
When Treatment Is Mitigated by Adverse Events: The Economic Impact of Treatment-Associated Adverse Events in Cirrhotic Non-Responders Treated with Boceprevir or Telaprevir and Peginterferon Alpha/Ribavirin (2013) (0)
Retroperitoneal Abscess Following EUS-Guided Celiac Plexus Block: 1529 (2014) (0)
THU-308-More than 4 times higher healthcare costs for end-stage liver disease patients with non-alcoholic fatty liver disease/nonalcoholic steatohepatitis (2019) (0)
Clinical Epidemiology and Molecular Biology of Hepatitis C (1993) (0)
Health outcomes among surveyed patients infected with hepatitis C in the Chronic Hepatitis Cohort Study (CHeCS) (2017) (0)
S3066 Interferon Therapy for Chronic Hepatitis Delta Viral Infection (2022) (0)
Isolated Hepatitis B Core Antibody is a Frequent Serologic Profile Denoting Prior Type B Hepatitis: 400 (2009) (0)
P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies (2017) (0)
Novel Technique for Intradiverticular Advanced Adenoma Resection: 2164 (2014) (0)
3026 Rare Complication of Chronic Pancreatitis: Chronic Portal Vein Thrombus Causing Pre-Hepatic Portal Hypertension (2019) (0)
Targeted Adverse Outcomes in Acute Pancreatitis are Infrequent in Non-transferred Patients: Implications for Future Research Studies: 169 (2010) (0)
A1-4: Pragmatic and Adaptive Methods of Electronic Medical Record (EMR) Cohort Identification for Comparative Effectiveness Research (2013) (0)
Celiac Disease Should Be Considered in Patients with Cryptogenic Cirrhosis: 831 (2008) (0)
Mo1425 - Hepatitis C (HCV) Patients with HIV Co-Infection Demonstrate Unique Liver-Related Complications and Health Behaviors Compared to HCV Mono-Infected Patients (2018) (0)
Hepatic Manifestations of Systemic Diseases. (2023) (0)
Persistence of the hepatitis C viral genome in the kissing bug (Rhodnius prolixus) (2001) (0)
Hepatitis B testing in a large cohort of U.S. hepatitis C virus-infected patients (2017) (0)
Erratum: "R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin" (Hepatology (2008) vol. 48 (385-397) 10.1002/hep.22357) (2008) (0)
Is there a correlation between hepatic steatosis, fibrosis, body mass index and viral levels in americans with chronic hepatitis C? (2000) (0)
Treatment of Chronic Viral Hepatitis in Patients with Autoimmune Diseases (2002) (0)
Reply (2014) (0)
Aortitis in a Patient with Chronic Hepatitis C Virus Infection: 1816 (2016) (0)
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study (2023) (0)
A non-invasive serum fibrosis marker panel can consistently select chronic hepatitis C patients with minimal stage (F0–F1) fibrosis from more advanced disease (F2–F4) (2003) (0)
1307-P: Real-World Health-Care Costs Impacted by Diabetes Mellitus (DM) among Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) Patients with Advanced Liver Diseases (AdvLD) (2019) (0)
RISK FACTORS FOR SARS-COV-2 INFECTION AMONG PATIENTS WITH CHRONIC VIRAL HEPATITIS (2020) (0)
P0730 : Prevalence and characteristics of hepatitis C genotypes in the chronic hepatitis cohort study (CHeCS) (2015) (0)
1253-P: High Health-Care Utilization (HCU) and Costs Associated with Diabetes Mellitus (DM) and Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) in Medicare Patients (2019) (0)
LIVER Ef fi cacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid (2015) (0)
Rising and higher healthcare-resource-utilization (HCRU) and costs of Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH) patients with advanced liver disease-a US real-world-analysis. (2019) (0)
T.N.3 A GENOME-WIDE DNA METHYLATION STUDY IN MONOZYGOTIC TWINS DISCORDANT FOR PRIMARY BILIARY CIRRHOSIS (2010) (0)
Utility of Historical Data Compared to Lead-in Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir+Peginterferon Alfa-2B/Ribavirin (PR) (2011) (0)
Ileal Varices Causing Massive Gastrointestinal Hemorrhage in a Cirrhotic Patient: 689 (2010) (0)
HEPATITIS C VIRUS (HCV) PATIENTS IN A LARGE U.S. COHORT (2013) (0)
PS2-03: Chronic Hepatitis B Testing in US-born and Foreign-born Asia Pacific Islanders of Kaiser Permanente, Hawai’i (2012) (0)
Introducing ERCP in a Low Income Country: A Case Series From Rwanda Endoscopy Week (2018) (0)
Reply: To PMID 23813604. (2014) (0)
1115 IMPACT OF HCV TREATMENT AND DISEASE SEVERITY ON HEALTH CARE COSTS IN CHRONIC HCV PATIENTS: ANALYSIS OF A LARGE US PRIVATE HEALTH INSURANCE CLAIMS DATABASE (2012) (0)
Multifocal Splenic Steatosis in End Stage Cholestatic Liver Disease: 656 (2007) (0)
Editorial: how widespread and serious is non‐alcoholic fatty liver disease in the real world? Authors' reply (2020) (0)
The Benefits and Limitations of On-Site Smear Review During EUS-FNA for Pancreatic Adenocarcinoma: 236 (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stuart C. Gordon?

Stuart C. Gordon is affiliated with the following schools:

Wayne State University